Jupiter Neurosciences (NASDAQ:JUNS) Shares Down 4.6% – Should You Sell?

Jupiter Neurosciences, Inc. (NASDAQ:JUNS)’s share price traded down 4.6% during mid-day trading on Monday . The stock traded as low as $0.2250 and last traded at $0.2310. 1,872,972 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 18,390,686 shares. The stock had previously closed at $0.2421.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Jupiter Neurosciences Stock Down 4.6%

The firm has a market capitalization of $8.38 million, a PE ratio of -0.86 and a beta of 1.71. The firm’s fifty day simple moving average is $0.34 and its 200-day simple moving average is $0.65.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.23 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vestor Capital LLC lifted its position in Jupiter Neurosciences by 144,607.2% during the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the period. Yorkville Advisors Global LP bought a new position in Jupiter Neurosciences during the fourth quarter valued at approximately $135,000. Geode Capital Management LLC lifted its position in Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the period. Finally, Allen Capital Group LLC bought a new position in Jupiter Neurosciences during the fourth quarter valued at approximately $31,000.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.